全文获取类型
收费全文 | 48669篇 |
免费 | 3708篇 |
国内免费 | 2455篇 |
专业分类
耳鼻咽喉 | 254篇 |
儿科学 | 1372篇 |
妇产科学 | 487篇 |
基础医学 | 11507篇 |
口腔科学 | 403篇 |
临床医学 | 3749篇 |
内科学 | 13067篇 |
皮肤病学 | 590篇 |
神经病学 | 1331篇 |
特种医学 | 641篇 |
外国民族医学 | 7篇 |
外科学 | 2112篇 |
综合类 | 6324篇 |
现状与发展 | 18篇 |
预防医学 | 7038篇 |
眼科学 | 390篇 |
药学 | 2587篇 |
12篇 | |
中国医学 | 855篇 |
肿瘤学 | 2088篇 |
出版年
2024年 | 43篇 |
2023年 | 557篇 |
2022年 | 1064篇 |
2021年 | 2167篇 |
2020年 | 1685篇 |
2019年 | 1474篇 |
2018年 | 1491篇 |
2017年 | 1460篇 |
2016年 | 1737篇 |
2015年 | 2038篇 |
2014年 | 2848篇 |
2013年 | 3061篇 |
2012年 | 2793篇 |
2011年 | 3289篇 |
2010年 | 2705篇 |
2009年 | 2480篇 |
2008年 | 2422篇 |
2007年 | 2579篇 |
2006年 | 2317篇 |
2005年 | 2030篇 |
2004年 | 1792篇 |
2003年 | 1559篇 |
2002年 | 1245篇 |
2001年 | 1210篇 |
2000年 | 986篇 |
1999年 | 895篇 |
1998年 | 788篇 |
1997年 | 792篇 |
1996年 | 657篇 |
1995年 | 650篇 |
1994年 | 602篇 |
1993年 | 491篇 |
1992年 | 363篇 |
1991年 | 310篇 |
1990年 | 279篇 |
1989年 | 259篇 |
1988年 | 236篇 |
1987年 | 175篇 |
1986年 | 153篇 |
1985年 | 300篇 |
1984年 | 187篇 |
1983年 | 139篇 |
1982年 | 128篇 |
1981年 | 104篇 |
1980年 | 71篇 |
1979年 | 63篇 |
1978年 | 55篇 |
1977年 | 35篇 |
1976年 | 36篇 |
1974年 | 9篇 |
排序方式: 共有10000条查询结果,搜索用时 156 毫秒
51.
目的探讨极速实时荧光聚合酶链反应(polymerase chain reaction,PCR)、实时荧光PCR、酶联免疫吸附测定(enzyme-linked immunosorbent assay,ELISA)和胶体金免疫层析法(gold immunochromatography assay,GICA)4种方法检测新型布尼亚病毒的特异度和灵敏度,为发热伴血小板减少综合征的早期诊断提供依据。方法采集2017年6月1日至9月30日山东大学附属济南市传染病医院86例临床诊断为发热伴血小板减少综合征患者的血清样本,分别应用极速实时荧光PCR、实时荧光PCR、ELISA和GICA 4种方法进行检测。统计学分析采用χ^2检验。结果86份患者血清标本中,极速实时荧光PCR、实时荧光PCR、IgM-ELISA、IgG-ELISA、IgM-GICA、IgG-GICA的新型布尼亚病毒阳性分别为82份(95.34%)、79份(91.86%)、41份(47.67%)、8份(9.3%)、19份(22.09%)和3份(3.49%)。极速实时荧光PCR特异度为100%,灵敏度达到1×103拷贝/mL,3次重复扩增试验显示其Ct值变异系数均<2%。在发热伴血小板减少综合征进展的1期、2期、3期病程中,极速实时荧光PCR的阳性检出率为41份(97.62%)、34份(94.44%)、7份(87.50%),实时荧光PCR的阳性检出率为39份(92.86%)、33份(91.67%)、7份(87.50%),在1期和2期两个病程,极速实时荧光PCR阳性检出率略高;IgM-ELISA阳性检出率从1期(28.57%)到3期(87.50%)显著增高,2期、3期与1期相比,差异均有统计学意义(χ^2=8.347、7.561,均P<0.01);IgM-GICA的阳性检出率从1期(14.29%)到2期(33.33%)也有增高,差异有统计学意义(χ^2=3.962,P<0.05),但与其他方法相比,其检出率偏低。1期,实时荧光PCR阳性检出率显著高于ELISA(IgM和IgG)和GICA(IgM和IgG),差异均有统计学意义(χ^2=33.740、55.080、49.010、64.340,均P<0.01)。2期,实时荧光PCR的阳性检出率高于ELISA(IgM和IgG)和GICA(IgM和IgG),差异均有统计学意义(χ^2=7.700、46.720、23.700、50.630,均P<0.01)。3期,极速实时荧光PCR、实时荧光PCR和IgM-ELISA表现出同样高的阳性检出率,远高于IgG-ELISA和GICA(IgM和IgG)。实时荧光PCR阳性检出率和IgG-ELISA、IgM-GICA、IgG-GICA之间差异均有统计学意义(均χ^2=6.250,P<0.05)。结论极速实时荧光PCR在新型布尼亚病毒的早期检测中有更高的灵敏度和特异度,且重复性好、稳定度高,与传统实时荧光PCR相比大大缩短了扩增时间,对发热伴血小板减少综合征的早期快速诊断具有重要价值。 相似文献
52.
目的 研究乙型肝炎病毒(HBV)自身增强子I(enhancerI,ENHI)对HBV DNA疫苗免疫应答的影响。方法 采用PCR法以HBVadr亚型全基因DNA序列为模板分别扩增表面抗原(HBsAg)和HBsA-ENHI基因片段,重组到载体VR1012中,构建两种HBV DNA疫苗,转染CADS-7细胞及HepG2细胞并免疫BALB/c小鼠。采用蛋白印迹、ELISA、ELISPOT等方法检测其在COS-7和HepG2细胞内的表达及小鼠的体液及细胞免疫应答效果。结果 转染的HepG2和COS-7细胞均表达HBsAg;连接ENHI的HBV DNA疫苗转染HepG2细胞后HBsAg表达量明显升高,两种疫苗转染COS-7细胞表达HBsAg无明显差异;免疫小鼠后第2周产生HBsAb及HBsAg特异性细胞毒T淋巴细胞(CTL),两种疫苗免疫产生的HBsAb及HBsAg特异性CTL无明显差异。结论ENHI可使HBV DNA疫苗转染HepG2细胞表达HBsAg明显增加,对转染COS-7细胞表达HBsAg及接种BALB/C小鼠引起的免疫应答无明显影响。 相似文献
53.
目的研究丙型肝炎病毒(HCV)核心蛋白6号结合蛋白基因(Hcbp6)序列表达的调控机制。方法根据软件对启动子的预测,选取翻译起始密码子ATG上游3256bp及下游180bp的DNA序列,分成5段活性区域,分别以聚合酶链反应技术(PCR),肝母细胞瘤细胞系HePG2基因组DNA为模板,扩增该启动子DNA片段,将其克隆至PCAT3中,构建PCAT3-Hcbp6-P报告基因表达载体,将该质粒分别转染HePG2,NIH3T3细胞,用酶联免疫吸附法检测报告基因编码产物氯霉素乙酰转移酶(CAT)的表达活性。结果发现质粒pCAT3-Hcbp6-1066p和pCAT3-Hcbp6-240p能够指导CAT的表达,其平均吸光度值(4)是PCAT3-basic对照质粒的3.1倍和6.4倍。结论本研究克隆的启动子DNA序列具有转录活性,这一结果为研究HcbP6的调节机制,进一步阐明HCV核心蛋白的作用机制奠定了基础。 相似文献
54.
D Gröne† R Treudler† EM de Villiers‡ R Husak† CE Orfanos† ChC Zouboulis†§ 《Journal of the European Academy of Dermatology and Venereology》2006,20(2):202-205
Cidofovir is an acyclic nucleoside phosphonate with broad-spectrum activity against DNA viruses, including human papilloma virus (HPV). However, data on the efficacy of cidofovir in an immunosuppressive setting remain contradictory. We report for the first time on the promotion of the healing of recalcitrant warts in a patient with myelodysplastic syndrome with intravenous cidofovir treatment. 相似文献
55.
Hepatitis C virus (HCV) infection is a major health care issue in liver and kidney transplantation. Besides negatively affecting both patient and graft survival, HCV is associated with a heightened risk for new onset diabetes mellitus (NODM). The mechanisms underlying the diabetogenicity of HCV are complex but are likely to involve insulin resistance caused by inhibitory actions of the virus on insulin regulatory pathways in the liver. The resultant glucose dysregulation is an important determinant of increased morbidity and mortality in liver and kidney recipients. This review highlights the concerns for outcomes in HCV-positive liver and kidney transplant patients with particular focus on the interrelationship between hepatitis C and diabetes. Data about the potential role of calcineurin inhibitors, corticosteroids and mycophenolate mofetil in HCV infection and HCV-associated NODM will also be discussed. 相似文献
56.
MASAFUMI IKEDA SHIGETOSHI FUJIYAMA MOTOHIKO TANAKA MICHIO SATA TATSUYA IDE HIROSHI YATSUHASHI HIROSHI WATANABE 《Journal of gastroenterology and hepatology》2006,21(1):122-128
Background and Aim: This study investigated the clinical features of hepatocellular carcinoma in patients with sustained virological response to interferon for hepatitis C viral (HCV) infection. Methods: A total of 7715 patients with HCV infection were treated with interferon and followed up for more than 1 year after withdrawal of interferon in 64 Japanese hospitals and clinics between July 1988 and August 2001. Sustained virological response was obtained in 2515 (32.6%) patients. Of these 2515 patients, clinical data were collected for 38 patients in whom hepatocellular carcinoma developed. Sustained virological response was defined as HCV RNA negativity more than 6 months after the termination of interferon. Results: All patients were HCV RNA negative at the time of diagnosis of hepatocellular carcinoma. The median period until the detection of hepatocellular carcinoma was 4.7 years (range 1.4–9.0 years). There were significant improvements in hepatic function including serum albumin, aspartate aminotransferase, alanine aminotransferase, indocyanine green test, platelet count and histological activity grade in comparison with those before interferon therapy and at the onset of hepatocellular carcinoma. The maximum tumor size in patients without medical follow‐up for 1 year or more (median: 60 mm) was significantly larger than in patients who were periodically followed up for 6 months or less (median: 25 mm) (P = 0.002). Conclusions: The present findings emphasize the importance of regular medical follow up of patients with HCV infection, as even patients showing a sustained virological response to interferon and in whom hepatic function has improved have the potential to develop hepatocellular carcinoma. 相似文献
57.
采用免疫组织化学S-P法检测52例手术切除乳腺癌组织c-erbB-2蛋白和HSV-1、HSV-2表达情况。结果发现癌组织中c-erbB-2阳性34例(65.4%);HSV-1阳性38例(73.1%);HSV-2阳性15例(28.8%)。癌旁组织32例,阳性分别为3例(9.4%);12例(37.5%);2例(6.3%)。乳腺癌中c-erbB-2阳性率明显高于癌旁组织。乳腺癌及癌旁的HSV-1阳性率明 相似文献
58.
静脉毒瘾者84例HGV感染状况 总被引:8,自引:0,他引:8
目的调查庚型肝炎病毒(HGV)在静脉毒瘾者中的感染状况。方法采用逆转录聚合酶链反应(RT-PCR)检测84例静脉毒瘾者血浆标本。HGVRNA经热变性法提取后逆转录为cDNA,在HGV5′非编码区(5′NCR)设计两对引物进行巢式扩增,产物为238bp,并经限制性内切酶HpaⅡ鉴定扩增产物来自HGV。结果84例中有15例为HGVRNA阳性,阳性率为17.9%。HGVRNA阳性病例中11例合并丙型肝炎病毒感染(11/15)。结论静脉毒瘾者是HGV感染的高危人群;不洁注射是获得HGV感染的重要途径。 相似文献
59.
Cytologic evaluation of the CSF is often difficult when trying to distinguish between truly neoplastic and reactive cells. Several non-neoplastic conditions may be associated with atypical cells in the CSF, a fact the clinician has to consider to avoid inadequate aggressive theraphies. We report here three patients with infectious meningitis (due to Herpes zoster virus in two, and neuroborreliosis in one) and cytologically atypical cerebrospinal fluid lymphocytes. Further characterization showed that the pleocyrosis in these patients was of reactive origin. Cytomorphology is frequently insufficient and histochemical, immuncytochemical and cellular genome analysis techniques may help differentiate atypical reactive cells from neoplastic cells. 相似文献
60.
Hitoshi Tajiri M.D Kosuke Kozaiwa M.D Tokuzo Harada M.D Yoshikazu Ozaki M.D Kazunori Miki M.D Kazuo Shimizu M.D Shintaro Okada M.D. 《Pediatrics international》1991,33(3):323-326
We assessed the efficacy of a government-sponsored mass protection program in Osaka, Japan, for perinatal HBV infection in infants born to HBeAg positive HBV carrier mothers. We also evaluated the impact of optional follow-up procedures in such infants, including an evaluation of anti-HBs response and a booster dose of HBV vaccine for poor responders. The results demonstrated that this mass protection program protected 94.4% of the infants from perinatal HBV infection in the Osaka area. However, the proportion of infants with an unprotective level of anti-HBs was higher in the standard group than in the follow-up group both at 1.0 and 1.5 years of age, which was also the case for HBV events. Furthermore, the present study showed that a booster dose of vaccine in poor responders was very effective in promoting an anti-HBs response. In conclusion, we recommend that a follow-up blood test to confirm a response of anti-HBs to HBV vaccine should be performed at 4–8 weeks after the third injection of HBV vaccine in infants born to HBeAg positive HBV carrier mothers. We also recommend that a booster injection of HBV vaccine should be immediately given to poor responding infants who otherwise are at a considerable risk of developing HBV infection in late infancy. 相似文献